By otakuyassine3@gmail.com 
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $75.00.
Several equities research analysts have commented on KROS shares. Jefferies Financial Group started coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. Guggenheim cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, December 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Wells Fargo & Company boosted their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.
Get Our Latest Analysis on Keros Therapeutics
Keros Therapeutics Stock Down 2.4 %
Shares of KROS stock opened at $16.71 on Wednesday. The company has a market capitalization of $676.87 million, a price-to-earnings ratio of -3.21 and a beta of 1.20. Keros Therapeutics has a 12-month low of $15.67 and a 12-month high of $73.00. The firm has a fifty day moving average of $54.10 and a 200-day moving average of $51.40.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.33) earnings per share. On average, equities analysts expect that Keros Therapeutics will post -5.26 EPS for the current year.
Institutional Investors Weigh In On Keros Therapeutics
A number of institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC raised its position in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. boosted its stake in shares of Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after buying an additional 89,952 shares during the period. Point72 Asset Management L.P. grew its position in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP increased its stake in Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after acquiring an additional 154,784 shares during the period. Institutional investors own 71.56% of the company’s stock.
Keros Therapeutics Company Profile
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
Receive News & Ratings for Keros Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Keros Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.